Eytan M. Stein, MD

Eytan M. Stein, MDAssistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. Dr. Stein is an Assistant Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center.

Dr. Stein conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. He led the clinical studies of the IDH2 inhibitor enasidenib and the IDH1 Inhibitor ivosidenib in patients with relapsed and refractory acute myeloid leukemia (AML) that led to FDA approval in 2017 and 2018. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the Beat AML® Master Clinical Trial. Dr. Stein’s current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery, and Blood. In addition, he serves on the editorial boards of Blood and Leukemia and Lymphoma.

Last modified: August 26, 2021

Authored Items